Population Pharmacokinetics and Exposure-response of Trametinib, a MEK Inhibitor, in Patients with BRAF V600 Mutation-positive Melanoma

Author(s): Daniele Ouellet, Nastya Kassir, Joannellyn Chiu, Mohamad-Samer Mouksassi, Cathrine Leonowens, Donna Cox, Douglas DeMarini, Olivia Gardner, Wendy Crist, Kiran Patel
Year: April 1, 2016
Learn More LinkedIn Twitter Facebook Email